NICE recommends Lundbeck migraine drug
The healthcare guidance provider for England and Wales says migraine treatment Vyepti is in line with competitors.
by christian bundgaard, translated by daniel pedersen
Lundbeck is continuing the rollout of its newest migraine therapy, Vyepti (eptinezumab), and the National Institute for Health and Care Excellence (NICE) has now made up its mind about where to put the treatment in guidelines for England and Wales.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Denmark rejects reimbursement for migraine drug Aimovig
For subscribers
Lundbeck's new long-term goals reflect growth confidence
For subscribers
.jpg&w=384&q=75)
